ADRB3 and cancer: As already reported in other cancer mouse models (Calvani et al., 2019; Bruno et al., 2020; Calvani et al., 2020), the treatment with β2-and β3-AR antagonists induced a significant reduction in tumor size (Figure 2A), thus confirming a pivotal role of β2-and β3-ARs in tumor growth.